openPR Logo
Press release

Cancer Immunotherapy Drugs Market Forecast, Share And Trends: 2017-2021

07-12-2017 02:40 PM CET | Advertising, Media Consulting, Marketing Research

Press release from: SA-BRC

Cancer Immunotherapy Drugs Market Forecast, Share And Trends:

Cancer immunotherapy drugs market leads the overall cancer therapeutics market due to its higher efficiency and lower side effects as compared to other drug classes. The U.S. FDA has been prompt in approval of novel immunotherapy drugs for treatment of various cancers. Tecentriq (atezolizumab) and Keytruda (pembrolizumab) were approved in 2016 for non-small cell lung cancer (NSCLC). Tecentriq was also approved for treatment of bladder cancer in May 2016, while Keytruda was approved for treatment of metastatic head and neck cancer, and melanoma. Earlier in 2015, the regulatory agency approved Darzalex (daratumumab) for the treatment for multiple myeloma.

The global cancer immunotherapy drugs market has been segmented into: monoclonal antibodies, therapeutic vaccines, check point inhibitors, and cytokines. By disease areas the market is segmented into lung cancer, breast cancer, colorectal cancer, prostate cancer, and others. Currently majority of the cancer immunotherapy drugs market is concentrated in the North America and Europe region due to higher diagnosis rate, and financial capability to afford expensive cancer treatment. National Cancer Institute, U.S. estimates over 1.68 million new cancer cases diagnosed in the U.S. in 21016. In U.K. 0.35 million new cancer cases were recorded according to Cancer Research U.K. Globally more than 8 million patients die due to cancer. Due to lack to data, accurate prevalence of cancer unknown in Africa; however it is estimated that 1.2 million new cases would be registered by 2030. Cancers with highest prevalence include lung cancer, breast cancer, colorectal cancer, prostate cancer, stomach cancer, liver cancer and cervical cancer in same order. Large percentage of cancer patients reside in low and middle income countries, where diagnosis rate is too low; maximum cases being diagnosed in the late stages. Thus large percentage of global population will continue to need cancer treatment in the future.

Request Free Report Sample@ http://www.sa-brc.com/Global-Cancer-Immunotherapy-Drugs-Market-Assessment--Forecast-2017-2021/up95

Increased government funding for cancer research and improved understanding of cancer biomarkers has helped in sourcing novel biologically actively molecules for treatment of various types of cancer. Technological advances in genetic sequencing and companion diagnostics has allowed targeted therapy with the immunotherapy drugs. These factors have provided necessary leverage for the overall market growth.

Erbitux (cetuximab), Herceptin (trastuzumab), Humira (adalimumab), Avastin (bevacizumab) are only a few of the blockbuster drugs expected to lose patent in the near future. Although mimicking biological drugs is a challenge in itself, various companies have been trying for regulatory approval for biosimilar drugs. Entry of biosimilar drugs is expected to make cancer immunotherapy drugs market open up in developing countries. Patent for trastuzumab expired in 2014 in the European Union (EU), while Remicade (infliximab) patent expired in 2014 in EU. New drug approval in the future is however expected to offset the overall market.

Request For TOC@ http://www.sa-brc.com/Global-Cancer-Immunotherapy-Drugs-Market-Assessment--Forecast-2017-2021/upcomingdetail95

Pipeline analysis of cancer immunotherapy drugs market is based on SA-BRC's in-house pharmaceutical drug analogue forecasting database. The database provides U.S. sales forecast of over 100 pharmaceutical brands approved for more than 50 disease indications. The proprietary database provides insights to annual drug sales in United States from year of approval till 2015, and forecast from 2016 to 2022.

NOTE: This report is currently under research and will be made available to clients on request.

About Us
Spearhead Acuity Business Research & Consulting Private Limited (SA-BRC) is a premium Life Science business intelligence and data analytics firm. SA-BRC team offers a wide range of business intelligence services to multiple stakeholders such as Medical Device Manufacturers, Service Providers (Hospitals, Payers, etc.), Suppliers, Group Purchase Organizations, Distributors and all other individuals in the entire value chain of healthcare industry. Our research and consulting capabilities extend across several sub-domains within the sphere of Life Sciences such as Biotechnology, Healthcare IT, Medical Devices, Veterinary Sciences, Wellness Products and Pharmaceuticals.

Contact Us
John Whitmore
Office No. 14,
Hermes Kunj, Mangaldas Road,
Pune, 411001
India
Phone: +91-02041210872
Email: sales@sa-brc.com
Website: www.sa-brc.com

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Cancer Immunotherapy Drugs Market Forecast, Share And Trends: 2017-2021 here

News-ID: 621163 • Views: 365

More Releases from SA-BRC

Biochip Market Analysis by Application and Trend 2017-2021
Biochips allow simultaneous testing of higher number of analytes to achieve high throughput and low cost per test. Nanotechnology has helped in miniaturization of devices to achieve higher performance standards. Microarrays are most important part of biochips which send signals to the biochip to deliver end results. Microfluidic biochips have become modern alternative to routine laboratories. Microfluidic technology which enables controlling flow of liquids in micro and pico quantities has
Acute Myeloid Leukemia Therapeutics Market Share, Analysis and Segments 2017-202 …
Acute myeloid leukemia is a cancer of blood cells and involves proliferation of abnormal blood cell types and subsequent replacement of bone marrow with cancerous cells. Major leukemia types include myeloblastic, promyeloctic, myelomonocytic, monocytic, erythroleukemia, megakaryocytic. Treatment of leukemia mainly depends on the type of leukemia and stage. Acute myeloid leukemia therapeutics market is rich with branded as well as generic drugs classified under various classes including antineoplastic agents, corticosteroids, tyrosine
Companion Diagnostics Market Share, Trends Analysis: 2017-2021
Companion diagnostics has revolutionized cancer therapeutics and enabled physicians to select specific treatment pattern from of myriad of drugs for cancer treatment. This has improved treatment outcome manyfold and has now become and indispensable part of personalized medicine. The companion diagnostics market received great attention post success of Herceptin (trastuzumab) and Gleevec (imatinib). Rapid adoption of companion diagnostics and supportive regulatory agencies have encouraged researchers to seek molecules that target
North America and Europe Bionic Eye Market Segment Analysis And Forecast: 2017-2 …
Sudden surge in bionic eye market was experienced recently after the National Health Service (NHS) announced the sponsorship to implant bionic eyes in ten patients. The bionic eye can help regain vision in individuals with visual impairment. Although currently two bionic eye systems has received regulatory approvals, other companies in the bionic eye market are also trying to develop new technology that can help in regaining visual sense in patients. The

All 5 Releases


More Releases for Cancer

Cancer Vaccines Market
Manufacturers in the cancer vaccines market are focusing on developing new vaccines in order to treat various cancers. Through this, they are expected to gain a competitive edge in the market and increase their market share. For instance, Gilead Science Inc., in 2017, acquired Kite Pharma Inc., which is involved in development of different type of immunotherapy and vaccines. Also, Treos Bio, in 2017, collaborated with Pharmaceutical Product Development, LLC
Oncology Nutrition Market by Cancer Type Breast Cancer, Liver Cancer, Lung Cance …
Lunch of new products for nutrition of oncology patients is expected to drive the oncology nutrition market growth. For instance, in 2016, Hormel Food Corporation, a U.S-based meat food products company, launched a line of packaged ready-to-eat meals for cancer patients, which are called as Hormel Vital Cuisine. These meals consist of carbohydrates, proteins, and fats to help patients fight loss of muscle mass and energy during cancer treatment. Thus launch
Cancer Molecular Biomarkers Market
Cancer molecular biomarkers refer to naturally-occurring molecules or genes in living organisms, which is an indicator for the presence of cancer in the body. A biomarker is a measurable indicator of biological process, condition, or disease and can be found in the blood, tissues, or other body fluids. Cancer molecular biomarkers help to diagnose cancer and monitor patients’ responses to treatments. On the basis of diagnostics, the cancer molecular
Cancer Diagnostics Global Market: By Application - Breast Cancer, Lung Cancer, C …
Researchmoz added Most up-to-date research on "Cancer Diagnostics Global Market: By Application - Breast Cancer, Lung Cancer, Colorectal Cancer, Melanoma & Other Cancers" to its huge collection of research reports. This report studies Cancer Diagnostics in Global market, especially in North America, China, Europe, Southeast Asia, Japan and India, with production, revenue, consumption, import and export in these regions, from 2012 to 2016, and forecast to 2022. This report focuses on top
Global Cancer Vaccines Market 2016: Liver cancer, Cervical cancer, Stomach cance …
Latest industry research report on Cancer vaccines are the type of immunotherapy (also named as biologic therapy), designed to boost body's natural defense against cancer. The body's natural immune system recognizes vaccine proteins as the foreign particles and sets up an immunity against them. According to World Health Organization (WHO), cancer is a leading cause of worldwide mortality registering ~14 million new cases and ~8.2 million cancer-related diseases in 2012. Personalized
Taking thyroid cancer seriously
With the increasing incidence rate of thyroid cancer in Metro Cebu, the Eduardo J. Aboitiz Cancer Center (EJACC) of the Ramon Aboitiz Foundation Inc. (RAFI) urged the public to undergo early screening and prevention measures to fight the disease. “Thyroid cancer is high on prognosis. It is preventable through various screening methods, such as physical examination and ultrasound of the neck, as well as some prevention measures, including regular exercise and